Subscribe To
Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion
On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic kidney disease, a Phase II trial in triple-...
November 2, 2023, 8:29 pm
Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...
October 20, 2023, 8:13 am
Alx oncology: on right track with latest interim analysis of evorpacept
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastr...
October 9, 2023, 12:38 am
Alx oncology stock doubles on early data from phase ii cancer trial
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing th...
October 3, 2023, 8:47 am
Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...
May 25, 2023, 5:10 pm
Merck's (mrk) keytruda sbla accepted by fda for gastric cancer
Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treat...
April 14, 2023, 3:12 pm
Zymeworks shares gain on promising data for cancer drug in development with jazz pharmaceuticals
Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their ex...
January 19, 2023, 8:07 am
Phathom pharmaceuticals announces positive topline results from phase 3 phalcon-nerd-301 trial evaluating daily dosing of vonoprazan for symptomatic non-erosive gastroesophageal reflux disease (nerd)
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn fre...
January 8, 2023, 11:00 pm
Phathom pharmaceuticals reports third quarter 2022 financial results and provides business updates
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosin...
November 8, 2022, 10:00 pm
Leap therapeutics to present new data from distinguish study of dkn-01 plus tislelizumab and waking study of dkn-01 plus tecentriq® at the esmo congress
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding bench...
September 4, 2022, 6:05 pm
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am